People14d
‘Micro-Retiring’ for Mental Health Is a Gen Z Trend — but Experts Say It Could 'Put You in a Backseat' in Your Career
Her work has previously appeared in Billboard and Reader's Digest. Getty Gen Z is “micro-retiring” — taking lengthy breaks from work that extend beyond a simple vacation — claiming that it ...
Morningstar14d
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk
--Up 15.27% month-to-date; on pace for best month since May 2024, when it rose 15.92% --Up 15.27% year-to-date --Down 10.17% from its all-time closing high of $516.74 on Nov. 8, 2024 --Up 9.3% ...
BioWorld14d
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
Business Insider15d
Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $550.00. Michael Yee’s rating is based on Vertex ...
Business Insider15d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...
Investing15d
Vertex Pharma shares jump on FDA approval for its non-opioid painkiller
Investing.com-- Vertex Pharmaceuticals Inc (NASDAQ:VRTX) shares jumped in extended trading on Thursday, following the U.S. Food and Drug Administration's approval of JOURNAVX, the company's new ...
Pharm Exec15d
FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
The FDA has approved Vertex Pharmaceuticals’ Journavx (suzetrigine), a first-in-class, non-opioid pain signal inhibitor for adults with moderate-to-severe acute pain. According to the company, the ...
The News & Advance15d
FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It's the first new pharmaceutical approach to ...
Investing15d
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug ...
Yahoo News15d
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
The movement to steer pain treatment away from opioids notched a major victory Thursday, as the Food and Drug Administration approved a new, highly anticipated drug from Vertex Pharmaceuticals. The ...
Investing15d
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new ...